- Home
- PPBT vs PALI Comparison
PPBT vs PALI Comparison
Compare PPBT & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- PALI
- Stock Information
- Founded
- PPBT 2010
- PALI 1996
- Country
- PPBT Israel
- PALI United States
- Employees
- PPBT N/A
- PALI N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PPBT Health Care
- PALI Health Care
- Exchange
- PPBT Nasdaq
- PALI Nasdaq
- Market Cap
- PPBT 5.5M
- PALI 5.9M
- IPO Year
- PPBT N/A
- PALI N/A
- Fundamental
- Price
- PPBT $0.58
- PALI $1.74
- Analyst Decision
- PPBT Strong Buy
- PALI Strong Buy
- Analyst Count
- PPBT 1
- PALI 2
- Target Price
- PPBT $33.00
- PALI $12.00
- AVG Volume (30 Days)
- PPBT 408.1K
- PALI 14.9M
- Earning Date
- PPBT 11-14-2025
- PALI 11-11-2025
- Dividend Yield
- PPBT N/A
- PALI N/A
- EPS Growth
- PPBT N/A
- PALI N/A
- EPS
- PPBT N/A
- PALI N/A
- Revenue
- PPBT N/A
- PALI N/A
- Revenue This Year
- PPBT N/A
- PALI N/A
- Revenue Next Year
- PPBT N/A
- PALI N/A
- P/E Ratio
- PPBT N/A
- PALI N/A
- Revenue Growth
- PPBT N/A
- PALI N/A
- 52 Week Low
- PPBT $0.53
- PALI $0.53
- 52 Week High
- PPBT $13.95
- PALI $4.32
- Technical
- Relative Strength Index (RSI)
- PPBT 19.96
- PALI 72.62
- Support Level
- PPBT $0.57
- PALI $0.58
- Resistance Level
- PPBT $0.62
- PALI $2.28
- Average True Range (ATR)
- PPBT 0.03
- PALI 0.23
- MACD
- PPBT 0.06
- PALI 0.13
- Stochastic Oscillator
- PPBT 45.09
- PALI 66.32
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.